Active circulation vs single perfusion and single infusion for hyperthermic intraperitoneal chemotherapy in patients with peritoneal effusion of ovarian cancer
10.3781/j.issn.1000-7431.2017.33.338
- Author:
Baona WANG
1
Author Information
1. Department of Oncology, Second Affiliated Hospital of xi'An Jiaotong University
- Publication Type:Journal Article
- Keywords:
Ascites;
Hyperthermic intraperitoneal perfusion chemotherapy;
Ovarian neoplasms
- From:
Tumor
2017;37(10):1086-1091
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the efficacy between active circulation mode and single-irrigation and single-pumped mode for hyperthermic intraperitoneal perfusion in ovarian cancer patients with intraperitoneal effusion. Methods: Fifty-three ovarian cancer patients with intraperitoneal effusion treated with active circulation mode of hyperthermic intraperitoneal perfusion between March 2016 and May 2017 were taken as study group, and another 51 ovarian cancer patients with intraperitoneal effusion treated with single-irrigation and single-pumped mode of hyperthermic intraperitoneal perfusion between July 2015 and February 2016 were taken as control group. All of the patients received hyperthermic intraperitoneal chemotherapy with paclitaxel and cisplatin. Each treatment was administered 3 times and treated for 2 cycles. The temperature duration time of perfusion fluid into and out of the abdominal cavity and the response rate of two groups were compared. Results: The temperature threshold of perfusate into the abdominal cavity of two groups can be controlled between 43.0-43.5 °. The abdominal temperature of study group was 41.0-41.5 ° and remained constant. The response rates of peritoneal effusion in study group and the control group were 86.8% (46/53) and 64.7% (33/51), respectively; there was a significant difference between the two groups (P < 0.05). Except for abdominal pain, the incidence rates of adverse reactions had no statistical differences (all P > 0.05). Conclusion: Active circulation mode of hyperthermic intraperitoneal perfusion has the advantages of constant temperature, short treatment time, high safety and remarkable curative effect in the treatment of peritoneal effusion of ovarian cancer, and is worthy of promotion in clinical practice.
